Compare Stocks

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
SMMT Summit Therapeutics	$3.59 -3.8%	$4.12	$1.30 ▼ $5.22	$2.52B	-1.21	2.19 million shs	1.28 million shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SMMT Summit Therapeutics	+6.88%	+5.37%	+10.68%	-15.80%	+147.02%

The A.I. story nobody is telling you (Read ASAP) (Ad)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	2.0174 of 5 stars	3.5	1.0	0.0	0.0	3.1	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	3.00	Buy	$8.00	122.84% Upside

Current Analyst Ratings

Latest AVEO and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/26/2024	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
SMMT Summit Therapeutics	$700K	3,598.72	N/A	N/A	$0.11 per share	32.64

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
SMMT Summit Therapeutics	-$614.93M	-$1.53	N/A	N/A	N/A	N/A	-87.45%	-41.17%	5/9/2024 (Estimated)

Latest AVEO and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/20/2024	Q4 2023	SMMT Summit Therapeutics	N/A	-$0.05	-$0.05	-$0.05	N/A	$0.20 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
SMMT Summit Therapeutics	1.29	9.30	9.30

Ownership

Institutional Ownership

Company	Institutional Ownership
AVEO AVEO Pharmaceuticals	49.95%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
AVEO AVEO Pharmaceuticals	3.29%
SMMT Summit Therapeutics	83.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
SMMT Summit Therapeutics	105	701.70 million	114.38 million	Optionable

AVEO and SMMT Headlines

Source	Headline
	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 businesswire.com - April 24 at 4:30 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 10.6% marketbeat.com - April 23 at 3:43 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14 americanbankingnews.com - April 23 at 5:34 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Rises By 28.6% americanbankingnews.com - April 15 at 5:40 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.7% americanbankingnews.com - April 14 at 5:50 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6% marketbeat.com - April 13 at 7:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7% marketbeat.com - April 12 at 3:59 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors finance.yahoo.com - April 11 at 5:11 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com - April 11 at 4:30 PM
	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum businesswire.com - April 10 at 7:00 AM
	Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor reuters.com - April 9 at 4:33 PM
	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer prnewswire.com - April 9 at 4:05 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95 marketbeat.com - April 4 at 2:02 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6% marketbeat.com - April 1 at 4:50 PM
	Summit Therapeutics CEO acquires shares worth over $411k investing.com - March 29 at 8:13 PM
	Why Summit Therapeutics Stock Crushed the Market This Week fool.com - March 29 at 5:43 PM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stock insidertrades.com - March 29 at 7:14 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying Activity marketbeat.com - March 28 at 10:31 AM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of Stock marketbeat.com - March 27 at 9:29 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28 marketbeat.com - March 26 at 12:25 PM
	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 businesswire.com - March 14 at 7:00 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT prnewswire.com - March 11 at 6:05 PM
	Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT accesswire.com - March 6 at 4:40 AM
	Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation accesswire.com - March 6 at 4:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Summit Therapeutics

NASDAQ:SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial